

友邦《海外特定药品列表》

2024年11月（V1.0版）

说明：

本列表所含药品，须严格按照治疗地的医疗或药品监督管理机构（释义一）批准的适应症凭治疗地执业医师的处方使用。

释义一 医疗或药品监督管理机构：指所在国或地区负责监管药品、医疗器械、食品安全以及相关公共卫生事项的行政机构，各国有不同的监督管理机构。例如：美国食品药品监督管理局（FDA: Food and Drug Administration）欧洲药品管理局（EMA: European Medicines Agency）；日本医药品医疗器械管理局（PMDA: Pharmaceuticals and Medical Devices Agency）等。

序号	通用名/商品名	适应症 (若中文与英文适应症不一致，以英文为准)		恶性肿瘤- 重度类型
1	Avelumab/Bavencio	Indicated for: ※ Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).	适用于: ※ 治疗转移性Merkel细胞癌的成人和12岁及以上儿童患者。	Merkel细胞癌
		Indicated for: ※ Maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. ※ Patients with locally advanced or metastatic UC who: • Have disease progression during or following platinum-containing chemotherapy. • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.	适用于: ※ 一线含铂化疗未进展的局部晚期或转移性尿路上皮癌患者的维持治疗。 ※ 符合以下条件的局部晚期或转移性尿路上皮癌患者: • 在含铂化疗期间或之后出现疾病进展。 • 在使用含铂化疗药物进行新辅助治疗或辅助治疗后12个月内出现疾病进展。	尿路上皮癌
		Indicated for: ※ First-line treatment, in combination with axitinib, of patients with advanced RCC.	适用于: ※ 与阿西替尼联合用于晚期肾细胞癌患者的一线治疗。	肾细胞癌
2	Cemiplimab-rwlc/Libtayo	Indicated for: ※ In combination with platinum - based chemotherapy for the first - line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: • Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or • Metastatic. ※ As single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score	适用于: ※ 与铂类化疗联合用于一线治疗无EGFR、ALK或ROS1突变的非小细胞肺癌成人患者，并且符合以下条件: • 局部晚期的，不适合手术切除或根治性放化疗，或 • 转移性的。 ※ 作为单药一线治疗非小细胞肺癌成人患者，患者的肿瘤具有高PD-L1表达【肿瘤细胞阳性比例评分≥50%】（经FDA批准的检测确定），且	非小细胞肺癌

		(TPS) $\geq 50\%$] as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is: • Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or • Metastatic.	无EGFR、ALK或ROS1突变, 并且符合以下条件: • 局部晚期的, 不适合手术切除或根治性放化疗, 或 • 转移性的。	
		Indicated for: ※ The treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.	适用于: ※ 治疗不适合根治性手术或根治性放疗的转移性皮肤鳞状细胞癌 或局部晚期皮肤鳞状细胞癌患者。	皮肤鳞状细胞癌
		Indicated for: ※ The treatment of patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ※ The treatment of patients with metastatic basal cell carcinoma (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.	适用于: ※ 治疗既往接受过Hedgehog信号通路抑制剂治疗或不适合Hedgehog信号通路抑制剂治疗的局部晚期基底细胞癌患者。 ※ 治疗既往接受过Hedgehog信号通路抑制剂治疗或不适合Hedgehog信号通路抑制剂治疗的转移性基底细胞癌患者。	基底细胞癌
3	Necitumumab/Portrazza	Indicated for: ※ In combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.	适用于: ※ 与吉西他滨和顺铂联合用于一线治疗转移性鳞状非小细胞肺癌患者。	非小细胞肺癌
4	Cobimetinib/Cotellic	Indicated for: ※ The treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.	适用于: ※ 与维莫非尼联合治疗BRAF V600E或V600K突变的不可切除或转移性黑色素瘤成人患者。	黑色素瘤
		Indicated for: ※ As a single agent for the treatment of adult patients with histiocytic neoplasms.	适用于: ※ 单药治疗组织细胞肿瘤成人患者。	组织细胞肿瘤
5	Tucatinib/Tukysa	Indicated for: ※ In combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.	适用于: ※ 与曲妥珠单抗和卡培他滨联合用于治疗晚期不可切除或转移性HER2阳性乳腺癌成人患者, 包括脑转移患者, 这些患者之前在转移性环境中接受过一种或多种基于抗HER2的治疗方案。	乳腺癌
		Indicated for: ※ In combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with	适用于: ※ 与曲妥珠单抗联合用于治疗RAS野生型HER2阳性不可切除或转移性结直肠癌成人患者, 这些患者在接受基于	结直肠癌

		fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.	氟嘧啶、奥沙利铂和伊立替康的化疗后病情进展。	
6	Alpelisib/Piqray	Indicated for: ※ In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.	适用于: ※ 与氟维司群联合治疗HR阳性、HER2阴性、PIK3CA突变、晚期或转移性乳腺癌的绝经后女性及男性患者, 这些患者在内分泌治疗方案中或治疗后出现进展并经FDA批准的检测确认。	乳腺癌
7	Panitumumab/Vectibix	Indicated for: ※ The treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): • In combination with FOLFOX for first-line treatment. • As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. Limitation of Use: VECTIBIX is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.	适用于: ※ 治疗野生型RAS (根据FDA批准的检测确定在KRAS和NRAS中定义为野生型) 转移性结直肠癌患者, 并且符合以下条件: • 与FOLFOX化疗方案联合用于一线治疗。 • 既往使用氟嘧啶、奥沙利铂和含伊立替康的化疗后疾病进展后的单一疗法。 使用限制: VECTIBIX不适用于治疗RAS突变转移性结直肠癌患者或RAS突变状态未知的患者。	结直肠癌
8	Ziv-aflibercept/Zaltrap	Indicated for: ※ In combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.	适用于: ※ 与氟尿嘧啶、亚叶酸钙、伊立替康 (FOLFIRI化疗方案) 联合治疗对含奥沙利铂方案耐药或病情进展的转移性结直肠癌患者。	结直肠癌
9	Encorafenib/Braftovi	Indicated for: ※ In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.	适用于: ※ 与西妥昔单抗联合治疗转移性结直肠癌成人患者, 患者在既往治疗后经FDA批准的检测确定为BRAF V600E突变。	结直肠癌
		Indicated for: ※ In combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.	适用于: ※ 与比美替尼联合治疗经FDA批准的检测确定为BRAF V600E突变的转移性非小细胞肺癌成人患者。	非小细胞肺癌
		Indicated for: ※ In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	适用于: ※ 与比美替尼联合治疗经FDA批准的检测确定为BRAF V600E或V600K突变的不可切除或转移性黑色素瘤患者。	黑色素瘤

10	Rucaparib/Rubraca	Indicated for: ※ The treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.	适用于: ※ 治疗存在有害BRCA突变（胚系和/或体细胞）相关的转移性去势抵抗性前列腺癌的成人患者，患者已接受雄激素受体导向疗法和紫杉烷类的化疗。根据FDA批准的RUBRACA伴随诊断选择患者治疗。	前列腺癌
		Indicated for: ※ The maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.	适用于: ※ 对铂类化疗完全或部分缓解的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者的维持治疗。	卵巢癌
11	Temsirolimus/Torisel	Indicated for: ※ Treatment of advanced renal cell carcinoma.	适用于: ※ 治疗晚期肾细胞癌。	肾细胞癌
12	Cabozantinib/Cabometyx	Indicated for: ※ The treatment of patients with advanced renal cell carcinoma (RCC). ※ The treatment of patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab.	适用于: ※ 治疗晚期肾细胞癌患者。 ※ 治疗晚期肾细胞癌患者，与纳武单抗联合作为一线治疗。	肾细胞癌
		Indicated for: ※ The treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	适用于: ※ 治疗既往接受过索拉非尼治疗的肝细胞癌患者。	肝细胞癌
		Indicated for: ※ The treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.	适用于: ※ 治疗12岁及以上患有局部晚期或转移性分化型甲状腺癌的成人和儿童患者，患者在既往接受过VEGFR靶向治疗后疾病进展，且放射性碘难治或不符合条件。	分化型假甲状腺癌
13	Cabozantinib/Cometriq	Indicated for: ※ The treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).	适用于: ※ 治疗进展性转移性甲状腺髓样癌患者。	甲状腺髓样癌
14	Bosutinib/Bosulif	Indicated for: ※ The treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ※ The treatment of adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.	适用于: ※ 治疗新确诊或对既往治疗耐药或不耐受的慢性期费城染色体阳性慢性髓性白血病成人和1岁及以上儿童患者。 ※ 治疗对既往治疗耐药或不耐受的加速期或急变期费城染色体阳性慢性髓性白血病成人患者。	慢性髓性白血病

15	Ponatinib/Iclusig	<p>Indicated for:</p> <p>※ The treatment of adult patients with: Chronic Myeloid Leukemia (CML)</p> <ul style="list-style-type: none"> • Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. • Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. • T315I-positive CML (chronic phase, accelerated phase, or blast phase). <p>Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.</p>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <p>慢性髓性白血病</p> <ul style="list-style-type: none"> • 慢性期慢性髓性白血病, 对既往至少两种激酶抑制剂具有耐药性或不耐受。 • 没有其他激酶抑制剂适用的加速期或急变期慢性髓性白血病。 • T315I阳性慢性髓性白血病 (慢性期、加速期或急变期)。 <p>使用限制: ICLUSIG不适用且不推荐用于治疗新确诊的慢性期慢性髓性白血病患者。</p>	慢性髓性白血病
		<p>Indicated for:</p> <p>※ The treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</p> <ul style="list-style-type: none"> • Newly diagnosed Ph+ ALL, in combination with chemotherapy. • As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. 	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <p>费城染色体阳性急性淋巴细胞白血病</p> <ul style="list-style-type: none"> • 联合化疗, 治疗新确诊的费城染色体阳性急性淋巴细胞白血病。 • 作为单一疗法治疗无其他激酶抑制剂适应症的费城染色体阳性急性淋巴细胞白血病或T315I阳性费城染色体阳性急性淋巴细胞白血病。 	急性淋巴细胞白血病
16	Midostaurin/Rydapt	<p>Indicated for:</p> <p>※ The treatment of adult patients with:</p> <ul style="list-style-type: none"> • Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. <p>Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.</p>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <ul style="list-style-type: none"> • 新确诊的急性髓系白血病, 经FDA批准的检测确定为FLT3突变阳性, 并结合标准阿糖胞苷和柔红霉素诱导及阿糖胞苷巩固化疗。 <p>使用限制: RYDAPT不适用于急性髓系白血病患者单药诱导疗法。</p>	急性髓系白血病
		<p>Indicated for:</p> <p>※ The treatment of adult patients with:</p> <ul style="list-style-type: none"> • Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). 	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <ul style="list-style-type: none"> • 侵袭性系统性肥大细胞增多症、系统性肥大细胞增多症伴相关血液肿瘤或肥大细胞白血病。 	<p>侵袭性系统性肥大细胞增多症</p> <p>系统性肥大细胞增多症伴相关血液肿瘤</p> <p>肥大细胞白血病</p>

17	Idelalisib/Zydelig	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ The treatment of patients with: • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. <p>Limitations of use:</p> <ul style="list-style-type: none"> • ZYDELIG is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent nonHodgkin lymphomas. • ZYDELIG is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas. 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 治疗以下患者: • 与利妥昔单抗联合治疗, 因其他合并症而单独使用利妥昔单抗被认为是适当治疗的复发性慢性淋巴细胞白血病患者。 <p>使用限制:</p> <ul style="list-style-type: none"> • ZYDELIG 不适合也不推荐用于任何患者的一线治疗, 包括慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、滤泡性淋巴瘤和其他惰性非霍奇金淋巴瘤患者。 • ZYDELIG 不适合且不推荐与苯达莫司汀和利妥昔单抗联合使用, 或与利妥昔单抗联合用于治疗滤泡性淋巴瘤、小淋巴细胞淋巴瘤和其他惰性非霍奇金淋巴瘤患者。 	慢性淋巴细胞白血病
18	Ibritumomab Tiuxetan /Zevalin	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ The treatment of adult patients with: • relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). • previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 治疗患有以下疾病的成人患者: • 复发性或难治性、低级别或滤泡性B细胞非霍奇金淋巴瘤。 • 既往未经治疗的滤泡性非霍奇金淋巴瘤, 患者对一线化疗取得部分或完全缓解。 	非霍奇金淋巴瘤
19	Belinostat/Beleodaq	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ The treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 治疗复发性或难治性外周T细胞淋巴瘤的成人患者。 	外周T细胞淋巴瘤
20	Romidepsin/Istodax	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ The treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 治疗至少接受过一次全身治疗的皮肤T细胞淋巴瘤成人患者。 	皮肤T细胞淋巴瘤
21	Vorinostat/Zolinza	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ The treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 治疗在两次全身治疗后或期间出现进行性、持续性或复发性疾病的皮肤T细胞淋巴瘤患者的皮肤表现。 	皮肤T细胞淋巴瘤
22	Elotuzumab/Empliciti	<p>Indicated for:</p> <ul style="list-style-type: none"> ※ Combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. 	<p>适用于:</p> <ul style="list-style-type: none"> ※ 与来那度胺和地塞米松联合治疗既往已接受过一到三种治疗的多发性骨髓瘤成人患者。 	多发性骨髓瘤

		※ Combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.	※ 与泊马度胺和地塞米松联合治疗既往接受过至少两种治疗（包括来那度胺和蛋白酶体抑制剂）的多发性骨髓瘤成人患者。	
23	Vismodegib/Erivedge	Indicated for: ※ The treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.	适用于: ※ 治疗转移性基底细胞癌或手术后复发的局部晚期基底细胞癌或不适合手术且不适合放疗的基底细胞癌成人患者。	基底细胞癌
24	Vandetanib/Caprelsa	Indicated for: ※ The treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.	适用于: ※ 治疗不可切除的局部晚期或转移性有症状或进展性甲状腺髓样癌。 仅在审慎考虑CAPRELSA治疗的相关风险后, 才可对惰性、无症状或展疾病进展缓慢的患者使用CAPRELSA。	甲状腺髓样癌
25	Glasdegib/Daurismo	Indicated for: ※ In combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.	适用于: ※ 与低剂量阿糖胞苷联合治疗年龄≥75岁或因合并症而无法使用强化诱导化疗的新确诊急性髓系白血病成人患者。	急性髓系白血病
26	Tafasitamab-cxix /Monjuvi、Minjuvi	Indicated for: ※ In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).	适用于: ※ 与来那度胺联合治疗非特指型复发或难治性弥漫性大B细胞淋巴瘤, 包括源自低级别淋巴瘤的弥漫性大B细胞淋巴瘤, 以及不适合进行自体干细胞移植的成人患者。	弥漫性大B细胞淋巴瘤
27	Binimetinib/Mektovi	Indicated for: ※ In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	适用于: ※ 与恩拉非尼联合治疗经FDA批准的检测确定为BRAF V600E或V600K突变的不可切除或转移性黑色素瘤患者。	黑色素瘤
		Indicated for: ※ In combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.	适用于: ※ 与恩拉非尼联合治疗经FDA批准的检测确定为BRAF V600E突变的转移性非小细胞肺癌成人患者。	非小细胞肺癌
28	Tremelimumab/Imjudo	Indicated for: ※ In combination with durvalumab, for the treatment of adult patients with	适用于: ※ 与度伐利尤单抗联合治疗无法切除的肝细胞癌成人患者。	肝细胞癌

		unresectable hepatocellular carcinoma (uHCC).		
		Indicated for: ※ In combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.	适用于: ※ 与度伐利尤单抗和铂类化疗联合治疗无致敏性EGFR突变或ALK基因组肿瘤异常的转移性非小细胞肺癌成人患者。	非小细胞肺癌
29	Fedratinib/Inrebic	Indicated for: ※ The treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).	适用于: ※ 治疗中度至2度或高风险原发性或继发性（真性红细胞增多症后或原发性血小板增多症后）骨髓纤维化的成人患者。	骨髓纤维化
30	Sotorasib/Lumakras	Indicated for: ※ The treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.	适用于: ※ 治疗经FDA批准的检测确定为KRAS G12C突变的既往至少接受过一次全身治疗的局部晚期或转移性非小细胞肺癌成人患者。	非小细胞肺癌
31	Asciminib/Scemblix	Indicated for: ※ The treatment of adult patients with: • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). • Ph+ CML in CP with the T315I mutation.	适用于: ※ 治疗患有以下疾病的成人患者: • 处于慢性期的费城染色体阳性慢性髓性白血病, 既往接受过两种或两种以上TKI治疗。 • 处于慢性期的T315I突变费城染色体阳性慢性髓性白血病。	慢性髓性白血病
32	Nivolumab & Relatlimab-rmbw/Opdualag	Indicated for: ※ The treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.	适用于: ※ 治疗不可切除或转移性黑色素瘤成人及12岁或以上儿童患者。	黑色素瘤
33	Dostarlimab-gxly/Jemperli	Indicated for: ※ In combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H). ※ As a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not	适用于: ※ 与卡铂和紫杉醇联合使用, 然后以JEMPERLI作为单药治疗经FDA批准的检测确定为dMMR或MSI-H的原发性晚期或复发性子宫内膜癌成人患者。 ※ 作为单药治疗经FDA批准的检测确定为dMMR的复发性或晚期子宫内膜癌成人患者, 患者既往接受含铂治疗方案治疗期间或之后病情出现进展, 且不适合进行根治性手术或放疗。	子宫内膜癌

		candidates for curative surgery or radiation.		
		Indicated for: ※ As a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.	适用于: ※ 作为单药治疗经FDA批准的检测确定为dMMR的复发性或晚期实体瘤成人患者, 患者在既往治疗期间或治疗后病情出现进展, 且无理想替代治疗方案。	实体瘤
34	Tagraxofusp-erzs /Elzonris	Indicated for: ※ The treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.	适用于: ※ 治疗成人和2岁及以上儿童患者的母细胞性浆细胞样树突状细胞肿瘤。	母细胞性浆细胞样树突状细胞肿瘤
35	Tivozanib/Fotivda	Indicated for: ※ The treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.	适用于: ※ 治疗既往接受过两次或两次以上全身治疗的复发或难治性晚期肾细胞癌成人患者。	肾细胞癌
36	Sirolimus protein-bound/Fyarro	Indicated for: ※ The treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).	适用于: ※ 治疗局部晚期不可切除或转移性恶性血管周上皮样细胞瘤成人患者。	血管周上皮样细胞瘤
37	Enasidenib/Idhifa	Indicated for: ※ The treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	适用于: ※ 治疗经FDA批准的检测确定存在IDH2突变的复发或难治性急性髓系白血病成人患者。	急性髓系白血病
38	Cabazitaxel/Jevtana	Indicated for: ※ In combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.	适用于: ※ 与泼尼松联合治疗既往接受过含多西他赛治疗方案的转移性去势抵抗性前列腺癌患者。	前列腺癌
39	Adagrasib/Krazati	Indicated for: ※ The treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.	适用于: ※ 治疗经FDA批准的检测确定为KRAS G12C突变的局部晚期或转移性非小细胞肺癌成人患者, 患者既往至少接受过一次全身治疗。	非小细胞肺癌
40	Mosunetuzumab-axgb /Lunsumio	Indicated for: ※ The treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.	适用于: ※ 治疗既往接受两次或两次以上全身治疗后复发或难治性滤泡性淋巴瘤成人患者。	滤泡性淋巴瘤
41	Futibatinib/Lytgobi	Indicated for: ※ The treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.	适用于: ※ 治疗既往接受过治疗的、不可切除的、局部晚期或转移性FGFR2基因融合或其他重排的肝内胆管癌成人患者。	胆管癌
42	Elacestrant/Orserdu	Indicated for:	适用于:	乳腺癌

		※ The treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.	※ 治疗ER阳性、HER2阴性、ESR1突变的晚期或转移性乳腺癌绝经后女性或成年男性患者，且患者在接受至少一线内分泌治疗后病情出现进展。	
43	Olutasidenib/Rezlidhia	Indicated for: ※ The treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.	适用于: ※ 治疗经FDA批准的检测确定为易感IDH1突变的复发或难治性急性髓系白血病成人患者。	急性髓系白血病
44	Tisotumab vedotin-tftv /Tivdak	Indicated for: ※ The treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.	适用于: ※ 治疗化疗期间或化疗后病情进展的复发性或转移性宫颈癌成人患者。	宫颈癌
45	Pacritinib/Vonjo	Indicated for: ※ The treatment of adults with intermediate or highrisk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below $50 \times 10^9/L$.	适用于: ※ 治疗血小板计数低于 $50 \times 10^9/L$ 的中或高风险原发性或继发性（真性红细胞增多症后或原发性血小板增多症后）骨髓纤维化的成人患者。	骨髓纤维化
46	Retifanlimab-dlwr/Zynyz	Indicated for: ※ The treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.	适用于: ※ 治疗转移性或复发性局部晚期Merkel细胞癌成人患者。	Merkel细胞癌
47	Gemtuzumab ozogamicin /Mylotarg	Indicated for: ※ Treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older. ※ Treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.	适用于: ※ 治疗新确诊的CD33阳性成人和1个月及以上儿童患者的急性髓系白血病。 ※ 治疗成人和2岁及以上儿童患者的复发性或难治性CD33阳性急性髓系白血病。	急性髓系白血病
48	Belzutifan/Welireg	Indicated for: ※ The treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.	适用于: ※ 治疗无需立即手术，需要接受肾细胞癌、中枢神经系统血管母细胞瘤或胰腺神经内分泌肿瘤相关治疗的von Hippel-Lindau病成人患者。	von Hippel-Lindau病
		Indicated for: ※ The treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).	适用于: ※ 治疗接受PD-1或PD-L1抑制剂和VEGF-TKI治疗后的晚期肾细胞癌成人患者。	肾细胞癌
49	Lutetium Lu 177 Dotatate /Lutathera	Indicated for: ※ The treatment of somatostatin receptor-positive gastroenteropancreatic	适用于: ※ 治疗生长抑素受体阳性胃肠胰神经内分泌肿瘤，包括	神经内分泌肿瘤

		neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.	成人患者前肠、中肠和后肠神经内分泌肿瘤。	
50	Lutetium Lu 177 vipivotide tetraxetan /Pluvicto	Indicated for: ※ The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.	适用于: ※ 治疗已接受AR通路抑制和紫杉烷类化疗治疗的PSMA阳性转移性去势抵抗性前列腺癌成人患者。	前列腺癌
51	Iobenguane I-131/Azedra	Indicated for: ※ The treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma who require systemic anticancer therapy.	适用于: ※ 治疗需要全身抗癌治疗的碘苄胍扫描阳性、不可切除、局部晚期或转移性嗜铬细胞瘤的成人和12岁及以上儿童患者。	嗜铬细胞瘤
		Indicated for: ※ The treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic paraganglioma who require systemic anticancer therapy.	适用于: ※ 治疗需要全身抗癌治疗的碘苄胍扫描阳性、不可切除、局部晚期或转移性副神经节瘤的成人和12岁及以上儿童患者。	副神经节瘤
52	Idecabtagene vicleucel /Abecma	Indicated for: ※ The treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.	适用于: ※ 治疗既往接受过两种或两种以上疗法（包括免疫调节剂、蛋白酶体抑制剂和抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤成人患者。	多发性骨髓瘤
53	Lisocabtagene maraleucel/Breyanzi	Indicated for: ※ The treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or • relapsed or refractory disease after two or more lines of systemic therapy. Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.	适用于: ※ 治疗患有大B细胞淋巴瘤的成人患者，包括非特指型弥漫性大B细胞淋巴瘤（包括源自惰性淋巴瘤的弥漫性大B细胞淋巴瘤）、高级别B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤和3B级滤泡性淋巴瘤，且： • 一线化学免疫疗法难治或一线化学免疫疗法后12个月内复发；或 • 一线化学免疫疗法难治或一线化学免疫疗法后复发且因合并症或年龄不适合进行造血干细胞移植；或 • 既往接受二线或二线上全身治疗后复发或难治。 使用限制：BREYANZI不适用于治疗原发性中枢神经系统淋巴瘤患者。	大B细胞淋巴瘤

		Indicated for: ※ The treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.	适用于: ※ 治疗复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤成人患者, 且既往至少接受过2种疗法, 包括BTK抑制剂和BCL-2抑制剂。	慢性淋巴细胞白血病 小淋巴细胞淋巴瘤
54	Tisagenlecleucel/Kymriah	Indicated for: ※ The treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.	适用于: ※ 治疗既往接受过二线或二线上全身治疗后复发或难治性大B细胞淋巴瘤成人患者, 包括非特指型弥漫性大B细胞淋巴瘤、高级别B细胞淋巴瘤和由滤泡性淋巴瘤引起的弥漫性大B细胞淋巴瘤。	大B细胞淋巴瘤
		Limitations of Use: KYMRIA is not indicated for treatment of patients with primary central nervous system lymphoma.	使用限制: KYMRIA不适用于治疗原发性中枢神经系统淋巴瘤患者。	
		Indicated for: ※ The treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.	适用于: ※ 治疗难治性或两次及以上复发的25岁及以下B细胞前体急性淋巴细胞白血病患者。	急性淋巴细胞白血病
55	Brexucabtagene autoleucel/Tecartus	Indicated for: ※ The treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	适用于: ※ 治疗复发或难治性B细胞前体急性淋巴细胞白血病成人患者。	急性淋巴细胞白血病
		Indicated for: ※ The treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	适用于: ※ 治疗复发或难治性套细胞淋巴瘤成人患者。	套细胞淋巴瘤
56	Ciltacabtagene autoleucel/Carvykti	Indicated for: ※ The treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.	适用于: ※ 治疗复发或难治性多发性骨髓瘤成人患者, 患者既往接受过至少一线治疗, 包括蛋白酶体抑制剂和免疫调节剂, 且对来那度胺有耐药性。	多发性骨髓瘤
57	Tebentafusp-tebn /Kimmtrak	Indicated for: ※ The treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.	适用于: ※ 治疗HLA-A*02:01阳性不可切除或转移性葡萄膜黑色素瘤成人患者。	葡萄膜黑色素瘤
58	Repotrectinib/Augtyro	Indicated for: ※ The treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).	适用于: ※ 治疗局部晚期或转移性ROS1阳性非小细胞肺癌成人患者。	非小细胞肺癌

59	Capmatinib/Tabrecta	Indicated for: ※ The treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.	适用于: ※ 治疗转移性非小细胞肺癌成人患者, 患者肿瘤具有MET14号外显子跳跃突变(经FDA批准的检测确定)。	非小细胞肺癌
60	Talazoparib/Talzenna	Indicated for: ※ As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.	适用于: ※ 单药治疗存在有害或疑似有害胚系BRCA突变、HER2阴性局部晚期或转移性乳腺癌成人患者。根据FDA批准的TALZENNA伴随诊断选择患者治疗。	乳腺癌
		Indicated for: ※ In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	适用于: ※ 与恩扎卢胺联合治疗HRR基因突变转移性去势抵抗性前列腺癌成人患者。	前列腺癌
61	Erdafitinib/Balversa	Indicated for: ※ The treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. Limitations of Use: BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.	适用于: ※ 治疗存在易感FGFR3基因突变的局部晚期或转移性尿路上皮癌成人患者, 且患者在既往接受过至少一种全身治疗期间或之后疾病出现进展。根据FDA批准的BALVERSA伴随诊断选择患者治疗。 使用限制: 不建议将BALVERSA用于符合资格但既往未接受过PD-1或PD-L1抑制剂治疗的患者。	尿路上皮癌
62	Enfortumab Vedotin-ejfv /Padcev	Indicated for: ※ In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ※ As a single agent for the treatment of adult patients with locally advanced or metastatic urothelial cancer who: • have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or • are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.	适用于: ※ 与帕博利珠单抗联合治疗局部晚期或转移性尿路上皮癌成人患者。 ※ 作为单药治疗局部晚期或转移性尿路上皮癌成人患者, 患者: • 既往接受过PD-1或PD-L1抑制剂和含铂化疗, 或 • 不适合接受含顺铂化疗, 既往接受过一种或多种治疗方案。	尿路上皮癌
63	Loncastuximab tesirine-lpyl/Zynlonta	Indicated for: ※ The treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of	适用于: ※ 治疗经过二线或二线上全身治疗后复发或难治性大B细胞淋巴瘤, 包括非特指型	弥漫性大B细胞淋巴瘤

		systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.	弥漫性大B细胞淋巴瘤、源自低级别淋巴瘤的弥漫性大B细胞淋巴瘤和高级别B细胞淋巴瘤的成人患者。	
64	Isatuximab-irfc/Sarclisa	Indicated for: ※ In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. ※ In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.	适用于: ※ 与泊马度胺和地塞米松联合治疗既往接受过至少2种治疗方案（包括来那度胺和蛋白酶体抑制剂）的多发性骨髓瘤成人患者。 ※ 与卡非佐米和地塞米松联合治疗既往接受过1至3种治疗方案的复发或难治性多发性骨髓瘤成人患者。	多发性骨髓瘤
65	Amivantamab-vmjw/Rybrevant	Indicated for: ※ In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. ※ As a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.	适用于: ※ 与卡铂和培美曲塞联合一线治疗经FDA批准的检测确定存在EGFR第20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者。 ※ 作为单药治疗经FDA批准的检测确定存在EGFR第20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者，且该患者在铂类化疗期间或之后病情出现进展。	非小细胞肺癌
66	Mirvetuximab soravtansine-gynx/Elahere	Indicated for: ※ The treatment of adult patients with FR α positive, platinum-resistant epithelial ovarian cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.	适用于: ※ 治疗FR α 阳性、铂耐药的卵巢上皮癌成人患者，既往已接受过一至三种全身治疗方案。根据FDA批准的检测选择患者进行治疗。	卵巢上皮癌
		Indicated for: ※ The treatment of adult patients with FR α positive, platinum-resistant fallopian tube cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.	适用于: ※ 治疗FR α 阳性、铂耐药的输卵管癌成人患者，既往已接受过一至三种全身治疗方案。根据FDA批准的测试选择患者进行治疗。	输卵管癌
		Indicated for: ※ The treatment of adult patients with FR α positive, primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.	适用于: ※ 治疗FR α 阳性、铂耐药的原发性腹膜癌成人患者，既往已接受过一至三种全身治疗方案。根据FDA批准的测试选择患者进行治疗。	原发性腹膜癌
67	Pirtobrutinib/Jaypirca	Indicated for: ※ The treatment of adult patients with relapsed or refractory mantle cell	适用于: ※ 治疗既往接受至少两线全身治疗（包括BTK抑制剂）	套细胞淋巴瘤

		lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.	的复发或难治性套细胞淋巴瘤成人患者。	
		Indicated for: ※ The treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.	适用于: ※ 治疗既往接受至少两线治疗（包括BTK抑制剂和BCL-2抑制剂）的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤成人患者。	慢性淋巴细胞白血病 小淋巴细胞淋巴瘤
68	Teclistamab-cqyv /Tecvayli	Indicated for: ※ The treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.	适用于: ※ 治疗既往接受过包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体在内的至少四线疗法的复发或难治性多发性骨髓瘤成人患者。	多发性骨髓瘤
69	Tazemetostat/Tazverik	Indicated for: ※ The treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	适用于: ※ 治疗不符合完全切除条件的转移性或局部晚期上皮样肉瘤的成人及16岁及以上的儿童患者。	上皮样肉瘤
		Indicated for: ※ The treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ※ The treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.	适用于: ※ 治疗复发性或难治性滤泡性淋巴瘤的成人患者，其肿瘤经FDA批准的检测确定为EZH2突变阳性，并且既往已接受至少两种全身治疗。 ※ 治疗无任何理想替代治疗方案的复发性或难治性滤泡性淋巴瘤的成人患者。	滤泡性淋巴瘤
70	Capivasertib/Truqap	Indicated for: ※ In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.	适用于: ※ 与氟维司群联合治疗HR阳性、HER2阴性、经FDA批准的检测确认伴有一种或多种生物标志物改变（PIK3CA、AKT1、PTEN）的局部晚期或转移性乳腺癌成人患者，患者在转移性环境中既往接受至少一种内分泌治疗后出现病情进展，或在完成辅助治疗后12个月内复发。	乳腺癌
71	Elranatamab/Elrexio	Indicated for: ※ The treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.	适用于: ※ 治疗患有复发性或难治性多发性骨髓瘤的成人患者，患者既往至少接受过四种疗法，包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体。	多发性骨髓瘤

72	Epcoritamab /Epkinly 、 Tepkinly	Indicated for: ※ The treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.	适用于: ※ 治疗既往接受过二线或多线全身治疗后的非特指型复发或难治性弥漫性大B细胞淋巴瘤成人患者, 包括源自惰性淋巴瘤的弥漫性大B细胞淋巴瘤和高级别B细胞淋巴瘤。	弥漫性大B细胞淋巴瘤
73	Momelotinib /Ojjaara 、 Omjjara	Indicated for: ※ The treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.	适用于: ※ 治疗成人贫血的中危或高危骨髓纤维化, 包括原发性骨髓纤维化或继发性骨髓纤维化(真性红细胞增多症后或原发性血小板增多症后)。	骨髓纤维化
74	Nirogacestat/Ogsiveo	Indicated for: ※ Adult patients with progressing desmoid tumors who require systemic treatment.	适用于: ※ 需要全身治疗的进展性硬纤维瘤成人患者。	硬纤维瘤
75	Quizartinib/Vanflyta	Indicated for: ※ In combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.	适用于: ※ 联合标准阿糖胞苷和蒽环类诱导治疗以及联合阿糖胞苷巩固治疗, 并作为巩固化疗后的单药维持治疗经FDA批准的检测确认为FLT3-ITD阳性的新确诊的急性髓系白血病人患者。 使用限制: VANFLYTA不适合作为同种异体造血干细胞移植后的维持单药治疗; 尚未证明VANFLYTA在这种情况下可改善总生存期。	急性髓系白血病
76	Talquetamab/Talvey	Indicated for: ※ The treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.	适用于: ※ 治疗复发性或难治性多发性骨髓瘤成人患者, 患者既往至少接受过四种疗法, 包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体。	多发性骨髓瘤

(此页内容结束)